Skip to main content

Novel Rx

Axial Spondyloarthritis
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference. Non-steroidal anti-inflammatory drugs (…
cancer search news magnify
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…
RT @Janetbirdope: #Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe

Janet Pope Janetbirdope

1 month ago
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
RT @doctorRBC: Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained R

Robert B Chao, MD doctorRBC

1 month ago
Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%) Less flare occurrences Sarilumab noted to have higher incidences of neutropenia, arthralgia @RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
RT @drdavidliew: Biosimilars and COVID vaccines have made nocebo more pertinent than ever.

How do we combat it?
First l

David Liew drdavidliew

1 month ago
Biosimilars and COVID vaccines have made nocebo more pertinent than ever. How do we combat it? First line is good communication, and the foot soldiers are the right phrases. Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G
RT @drdavidliew: Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.

In the 2022 version:
JAK

David Liew drdavidliew

1 month ago
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change. In the 2022 version: JAKi now separate sentence following bDMARDs, with proviso to mention risk. Sometimes guidelines have to tell us what we’ve all inevitably been expecting #EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
RT @Yuz6Yusof: #LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in

Md Yuzaiful Md Yusof Yuz6Yusof

1 month ago
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
RT @doctorRBC: Does treating spondyloarthritis early matter?
Systematic review showed in nr-axSpA tx with biologics may

Robert B Chao, MD doctorRBC

1 month ago
Does treating spondyloarthritis early matter? Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA axSpA - no difference in response between early vs. established disease @RheumNow #EULAR2022 ABST#POS0302
RT @AurelieRheumo: Sarilumab in PMR

SAPHYR Phase 3 RCT
Underpowered (<50% target recruitment)

-% remission sustaine

Aurelie Najm AurelieRheumo

1 month ago
Sarilumab in PMR SAPHYR Phase 3 RCT Underpowered (<50% target recruitment) -% remission sustained from wk12 to wk 52 28% vs 10% PBO -Risk of flare reduced HR 0.56 -Improvement of several PROs No new safety signal LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo
×